Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan Fowler

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
The Lancet. Oncology|June 9, 2012
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trialMichael Wang, Luis Fayad, Nicolaus Wagner-Bartak, et al.
Science Translational Medicine|November 20, 2015
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancerDavid Hong, Razelle Kurzrock, Youngsoo Kim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 15, 2019
Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with LymphomaNeeraj Y Saini, Rima M Saliba, Gabriela Rondon, et al.
Journal for Immunotherapy of Cancer|November 18, 2018
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trialMatthew J Reilley, Patricia McCoon, Carl Cook, et al.
British Journal of Haematology|June 20, 2014
Double hit lymphoma: the MD Anderson Cancer Center clinical experienceYasuhiro Oki, Mansoor Noorani, Pei Lin, et al.
JAMA Oncology|May 27, 2016
Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During PregnancyChelsea C Pinnix, Eleanor M Osborne, Dai Chihara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2021
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell LymphomaPreetesh Jain, Shuangtao Zhao, Hun Ju Lee, et al.
The New England Journal of Medicine|May 30, 2019
Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, Michael Keating, Philip Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2022
Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell LymphomaJason Westin, R Eric Davis, Lei Feng, et al.
Nature Medicine|October 6, 2020
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomasQing Deng, Guangchun Han, Nahum Puebla-Osorio, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
The Lancet. Oncology|June 9, 2012
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trialMichael Wang, Luis Fayad, Nicolaus Wagner-Bartak, et al.
Science Translational Medicine|November 20, 2015
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancerDavid Hong, Razelle Kurzrock, Youngsoo Kim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 15, 2019
Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with LymphomaNeeraj Y Saini, Rima M Saliba, Gabriela Rondon, et al.
Journal for Immunotherapy of Cancer|November 18, 2018
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trialMatthew J Reilley, Patricia McCoon, Carl Cook, et al.
British Journal of Haematology|June 20, 2014
Double hit lymphoma: the MD Anderson Cancer Center clinical experienceYasuhiro Oki, Mansoor Noorani, Pei Lin, et al.
JAMA Oncology|May 27, 2016
Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During PregnancyChelsea C Pinnix, Eleanor M Osborne, Dai Chihara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2021
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell LymphomaPreetesh Jain, Shuangtao Zhao, Hun Ju Lee, et al.
The New England Journal of Medicine|May 30, 2019
Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, Michael Keating, Philip Thompson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2022
Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell LymphomaJason Westin, R Eric Davis, Lei Feng, et al.
Nature Medicine|October 6, 2020
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomasQing Deng, Guangchun Han, Nahum Puebla-Osorio, et al.
Pageof 9